Acid-reducing drugs, also called proton pump inhibitors (PPI), are one of the most successful drug classes ever launched, projected to earn as much as $3.26 billion in profits in the year 2026.
“Twenty-five years after their introduction into clinical practice, PPIs remain the mainstay of the treatment of acid-related diseases,” research published in the journal BMC Medical says. “Overall, PPIs are irreplaceable drugs in the management of acid-related diseases.”
Comprising both prescription and over-the-counter preparations, PPIs are intended to treat acid diseases such as gastroesophageal reflux disease or GERD (which stems from stomach acid repeatedly back flowing into the esophagus) as well as other conditions such as heartburn, stomach discomfort, and the risk of gastrointestinal bleeding in ulcer patients or those using blood thinners, such as aspirin. More than 15 million Americans have been prescribed PPIs prescriptions and many others buy the drugs over the counter…. Source
Acid Blockers Raise Risk of COVID-19, Other Diseases
November 25th, 2022 Awake Goy
Peer Reviewed Studies Find COVID Always Less Deadly Than Flu & Injected Far More Likely To Get Sick
Epidemiologist Says COVID Vaccine is “Phase Two of a Bioterrorism Operation”
CDC Redacts Every Single Word of 148-Page Study on Myocarditis After Covid Vaccination
US Congress Works on COVID Aid as Another Shutdown Threat Looms
How one farm in Angola was successfully created during the COVID-19 pandemic
MEP leaves League over its backing for mandatory COVID health passes